GlassScriptPhysician profile
Furha Cossor
NPI 1760607360
$1,053.32
in general payments reported to CMS, 2019-2025
11 companies · $505 in 2025
The $505 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.90 · 2020: $132 · 2022: $118 · 2024: $287 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $791.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $220.79 | 2022-2024 | Ojjaara |
| Alnylam Pharmaceuticals INC. | $133.31 | 2025 | Amvuttra |
| Adc Therapeutics America, INC. | $130.82 | 2025 | |
| Incyte Corporation | $119.96 | 2020 | |
| Amgen INC. | $119.68 | 2024 | Blincyto |
| Janssen Biotech, INC. | $114.81 | 2025 | Carvykti, Rybrevant |
| Pharmaessentia USA Corporation | $110.97 | 2025 | Besremi |
| Pfizer INC. | $90.70 | 2019-2025 | |
| Eusa Pharma (US) LLC | $12.28 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Furha Cossor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.